Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 infant safety study of Pn MAPS30plus versus Prevenar
PACTR202605824103374Phase 1Not yet recruiting
- Sponsor
- GSK
- Start
- Jul 2026
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1 trial of pneumococcal 7-valent conjugate vaccine in pneumococcal disease (2 arms), sponsored by GSK. Primary endpoints: Solicited local and systemic adverse events within 7 days, Unsolicited adverse events within 30 days and 1 more. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
pneumococcal 7-valent conjugate vaccine
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on PACTR202605824103374.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202605824103374.